Selected stock price target news of the day - May 13th, 2025

By: Matthew Otto

Xenon Reports Q1 2025 Results and Advances Late-Stage and Early-Stage Pipeline

Xenon Pharmaceuticals reported a Q1 2025 net loss of $65.0 million, or ($0.83) per share, which was $0.08 better than the analyst consensus estimate of ($0.91). Revenue for the quarter was $7.5 million, exceeding the consensus estimate of $1.25 million.

Research and development expenses increased to $61.2 million from $44.3 million in Q1 2024. General and administrative expenses rose to $19.0 million, up from $14.8 million year-over-year. Cash, cash equivalents, and marketable securities totaled $691.1 million as of March 31, 2025.

Looking ahead, Xenon anticipates completing enrollment in the Phase 3 X-TOLE2 study for focal onset seizures (FOS) in the coming months, with topline data expected in early 2026. FOS affects approximately 2.2 million people in the U.S. and is the most common form of epilepsy in adults. If successful, azetukalner could provide a new treatment option for patients who are refractory to current therapies—up to 30% of epilepsy patients remain uncontrolled despite available medications.

Xenon is also expanding azetukalner’s use into neuropsychiatric conditions, with its second Phase 3 study in major depressive disorder (MDD), X-NOVA3, and a new trial in bipolar depression (BPD) set to begin mid-year. MDD affects over 21 million U.S. adults annually, while BPD impacts approximately 7 million.

Analysts Adjust Price Targets Following Q1 Beat and Pipeline Progress

Needham analyst Serge Belanger reiterated a Buy rating while lowering the price target from $60 to $55.
Chardan Capital analyst Rudy Li reaffirmed a Buy rating and a $55 price target.
Wells Fargo analyst Mohit Bansal reduced the price target to $47.
HC Wainwright & Co. analyst Douglas Tsao reiterated a Buy rating and a $53 price target.

Which Analyst has the best track record to show on XENE?

Analyst Laura Chico (WEDBUSH) currently has the highest performing score on XENE with 8/12 (66.67%) price target fulfillment ratio. Her price targets carry an average of $4.03 (9.60%) potential upside. Xenon Pharmaceuticals stock price reaches these price targets on average within 413 days.

Agenus Reports Progress in Cancer Drug Development and First Quarter 2025 Results

Agenus shared its first quarter 2025 results and important updates on its experimental cancer treatment—a drug combination called botensilimab (BOT) and balstilimab (BAL). New data from ongoing studies show this treatment is working in cancers that usually don’t respond to other immunotherapy drugs. These include colorectal cancer (CRC), triple-negative breast cancer (TNBC), liver cancer, and certain types of sarcomas.

Globally, more than 1.4 million people are diagnosed annually with CRC, including approximately 85% with MSS tumors—representing a patient population of over 1 million individuals who may benefit from new treatment options like BOT/BAL. Similarly, over 300,000 cases of TNBC and 400,000 cases of liver cancer are diagnosed annually, many of whom have limited options after first-line treatments.

Financially, Agenus reported a Q1 2025 net loss of $26.4 million, or ($1.03) per share, in line with its reported earnings per share. Revenue for the quarter came in at $24.07 million, below $28.0 million in the same period last year. Agenus reduced operational cash usage to $25.6 million, compared to $38.2 million in Q1 2024, and ended the quarter with $18.5 million in cash and cash equivalents, down from $40.4 million as of December 31, 2024.

Analysts Maintain Ratings as Clinical Progress and Cost Discipline Continue

HC Wainwright & Co. analyst Emily Bodnar reiterated her Neutral rating.
Baird analyst Colleen Kusy maintained a Neutral stance and raised her price target from $3 to $4.

Which Analyst has the best track record to show on AGEN?

Analyst Emily Bodnar (HC WAINWRIGHT) currently has the highest performing score on AGEN with 3/9 (33.33%) price target fulfillment ratio. Her price targets carry an average of $3.58 (104.68%) potential upside. Agenus stock price reaches these price targets on average within 285 days.

Rapid7 Reports Q1 2025 Financial Results and Strategic Updates

Rapid7 reported its first quarter in 2025, with annualized recurring revenue (ARR) of $837 million, reflecting a 4% increase year-over-year. Total revenue for Q1 reached $210.25 million, exceeding analysts’ expectations of $208.24 million. Product subscriptions revenue grew by 4% to $204 million, while professional services revenue declined by 23% to $6.3 million.

Rapid7’s operating income for the quarter stood at $32 million, with net income of $2.1 million, or $0.03 per share. Delivered earnings per share (EPS) of $0.43, which was $0.09 better than the consensus estimate of $0.34. Additionally, Rapid7 generated $30 million in net cash from operating activities and reported free cash flow of $25 million, demonstrating strong financial discipline.

Looking ahead, Rapid7 provided its guidance for the second quarter and full-year 2025. For Q2, Rapid7 anticipates revenue between $211 million and $213 million, below the consensus estimate of $217.7 million, and EPS between $0.43 and $0.46, in line with analyst expectations of $0.46.

For the full year, Rapid7 expects revenue in the range of $853 million to $863 million, which is below the consensus of $861.2 million. Full-year EPS guidance is projected between $1.78 and $1.91, compared to the consensus estimate of $1.84.

Analysts Adjust Price Targets Amidst Q1 Results and Market Uncertainty

Baird analyst Shrenik Kothari maintained a Neutral rating and raised the price target from $26 to $28.
DA Davidson analyst Rudy Kessinger downgraded from Neutral to Underperform and the price target from $29 to $21.
Scotiabank analyst Patrick Colville lowered the price target to $29.
Piper Sandler analyst Rob Owens adjusted the price target downward to $30.
Truist Securities analyst Joel Fishbein reduced the price target to $28.

Which Analyst has the best track record to show on RPD?

Analyst Brian Essex (JPMORGAN) currently has the highest performing score on RPD with 11/13 (84.62%) price target fulfillment ratio. His price targets carry an average of $1.18 (3.39%) potential upside. Rapid7 stock price reaches these price targets on average within 39 days.